Congratulations on Yung Shin Pharmaceutical for receiving recognition!
Taichung Dajia Youth Industiral Park Plant 2 was awarded the first animal enzyme factory in Taiwan to pass the new FAMI-QS [Version 6.0] certification.

 FAMI-QS Version 6 has two core pillars: quality and feed safety. It was built upon the standard ISO management system structure, risk-based thinking and a process-based approach. It strengthens the requirement for operators to understand the impact of their operating environment on feed safety, implement a Feed Fraud Prevention and Defence program, and develop a deep understanding of their processes and outputs.

 FAMI-QS was developed and promulgated by the European Feed Additives Industry Association (FEFANA) in Brussels, Belgium, on July 15, 2004. This standard provides industry compliance with operational systems and procedures, and serves as a management and oversight tool. This international organization established the basic requirements and rules for the feed industry based on EU Directives 831/2003/EC and 183/2005/EC. In addition to quality management system requirements, the standard also covers HACCP, incoming material handling, finished product manufacturing, transportation, cleaning, pest control, and product recall, strengthening the management structure while also prioritizing a product-focused regulatory approach.

In addition to its focus on human pharmaceuticals, Yung Shin Pharmaceutical has also been deeply involved in the animal healthcare market for many years. Vetnostrum Animal Health, a subsidiary of the Yung Shin Group specializing in animal pharmaceuticals and animal health products and continues to strengthen its diversified products, including high-quality animal pharmaceuticals, health products, vaccines, and feed additives to meet our customers' specific needs. Yung Shin Pharmaceutical achieve customer recognition, foster its innovation and is committed to keep rooted in Taiwan and expand internationally. By continuously optimizing its supply chain and strengthening its core competitiveness, Yung Shin Pharmaceutical together with the Yung Shin Group will become a globally competitive and influential enterprise.